Avacta Group (LSE:AVCT) Short Interest


LSE:AVCT Avacta Group PLC LSE:AVCT
28 GF Score
Price £0.72
GF Value £0.49
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Avacta Group Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

LSE:AVCT vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Avacta Group's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avacta Group Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avacta Group's Short Interest distribution charts can be found below:

* The bar in red indicates where Avacta Group's Short Interest falls into.


LSE:AVCT
28GF Score
Avacta Group PLC LSE:AVCT
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Avacta Group (LSE:AVCT) Overvalued in 2026?

Based on GuruFocus' analysis, Avacta Group stock appears to be overvalued. The current stock price of £0.72 is trading 47.3% above its estimated GF Value™ of £0.49. GuruFocus considers Avacta Group to be Significantly Overvalued.

Key valuation signals for LSE:AVCT:

  • Short Interest:
  • GF Value™: £0.49 vs. price of £0.72 (47.3% above fair value)
  • GF Score™: 28/100 with 8 warning signs

No single metric tells the full story. See the LSE:AVCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Avacta Group Business Description

Other Exchanges AVCTF:USARTQ1:Germany
Address 58 Wood Lane, White City Imperial College Campus, Scale Space, London, GBR, W12 7RZ
Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea.
28GF Score

Get the complete analysis for LSE:AVCT

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.72
Price
£0.49
GF Value